Neoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast Cancer
Status:
RECRUITING
Trial end date:
2029-06-30
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to evaluate the efficacy and safety of oral paclitaxel plus fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in the neoadjuvant treatment of HER2+ breast cancer patients.
Phase:
NA
Details
Lead Sponsor:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Collaborators:
Affiliated Cancer Hospital of Shantou University Medical College Cancer Hospital of Guangxi Medical University First Affiliated Hospital of Wenzhou Medical University Guangdong Women and Children Hospital Hainan People's Hospital Nanfang Hospital, Southern Medical University Peking University Cancer Hospital & Institute Peking University Shenzhen Hospital The Affiliated Hospital Of Guizhou Medical University